Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Immunome, Inc. stock logo
IMNM
Immunome
$8.89
+4.0%
$8.66
$5.15
$16.81
$743.95M1.92893,880 shs1.58 million shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$17.29
+2.4%
$15.41
$12.72
$34.47
$2.89B0.631.22 million shs1.47 million shs
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$45.18
+4.0%
$39.08
$19.45
$53.27
$2.83B2.18624,317 shs1.01 million shs
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
$19.50
$2.86B1.21.02 million shsN/A
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Immunome, Inc. stock logo
IMNM
Immunome
+3.98%+3.01%-4.10%+43.39%-28.88%
Immunovant, Inc. stock logo
IMVT
Immunovant
+2.37%+2.86%+6.14%+16.90%-41.78%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
+4.03%+1.46%-4.20%+101.70%+14.55%
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%+1.88%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Immunome, Inc. stock logo
IMNM
Immunome
1.9753 of 5 stars
3.52.00.00.01.12.50.0
Immunovant, Inc. stock logo
IMVT
Immunovant
1.3765 of 5 stars
3.52.00.00.00.01.70.0
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
3.145 of 5 stars
4.51.00.00.03.02.50.0
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Immunome, Inc. stock logo
IMNM
Immunome
3.00
Buy$23.33162.47% Upside
Immunovant, Inc. stock logo
IMVT
Immunovant
2.90
Moderate Buy$38.33121.71% Upside
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
3.00
Buy$59.1130.83% Upside
MorphoSys AG stock logo
MOR
MorphoSys
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest IMNM, KYMR, IMVT, and MOR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/3/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$70.00
6/27/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$56.00 ➝ $53.00
6/26/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$59.00
6/26/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$57.00 ➝ $53.00
6/26/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$54.00 ➝ $60.00
6/25/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$64.00
6/3/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$60.00
6/3/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$57.00 ➝ $64.00
6/3/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$38.00 ➝ $60.00
6/3/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$49.00 ➝ $79.00
5/13/2025
Immunome, Inc. stock logo
IMNM
Immunome
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$33.00 ➝ $21.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Immunome, Inc. stock logo
IMNM
Immunome
$9.04M85.57N/AN/A$2.27 per share3.92
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/A$4.16 per shareN/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$47.07M62.51N/AN/A$12.90 per share3.50
MorphoSys AG stock logo
MOR
MorphoSys
$238.28M11.99N/AN/A$0.35 per share54.17
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Immunome, Inc. stock logo
IMNM
Immunome
-$292.96M-$3.18N/AN/AN/A-1,875.21%-71.65%-60.36%8/11/2025 (Estimated)
Immunovant, Inc. stock logo
IMVT
Immunovant
-$413.84M-$2.74N/AN/AN/AN/A-80.60%-71.89%8/5/2025 (Estimated)
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$223.86M-$3.10N/AN/AN/A-409.07%-30.11%-25.65%8/6/2025 (Estimated)
MorphoSys AG stock logo
MOR
MorphoSys
-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/A

Latest IMNM, KYMR, IMVT, and MOR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$0.84N/AN/AN/A$17.37 millionN/A
8/5/2025Q1 2026
Immunovant, Inc. stock logo
IMVT
Immunovant
-$0.69N/AN/AN/AN/AN/A
5/29/2025Q4 2025
Immunovant, Inc. stock logo
IMVT
Immunovant
-$0.72-$0.64+$0.08-$0.64N/A$0.16 million
5/12/2025Q1 2025
Immunome, Inc. stock logo
IMNM
Immunome
-$0.66-$0.52+$0.14-$0.52$0.46 million$2.93 million
5/9/2025Q1 2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$0.92-$0.82+$0.10-$0.82$11.38 million$22.10 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Immunome, Inc. stock logo
IMNM
Immunome
N/AN/AN/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/AN/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Immunome, Inc. stock logo
IMNM
Immunome
N/A
10.49
10.49
Immunovant, Inc. stock logo
IMVT
Immunovant
N/A
11.16
11.16
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
8.49
8.49
MorphoSys AG stock logo
MOR
MorphoSys
4.98
1.38
1.38

Institutional Ownership

CompanyInstitutional Ownership
Immunome, Inc. stock logo
IMNM
Immunome
44.58%
Immunovant, Inc. stock logo
IMVT
Immunovant
47.08%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
MorphoSys AG stock logo
MOR
MorphoSys
18.38%

Insider Ownership

CompanyInsider Ownership
Immunome, Inc. stock logo
IMNM
Immunome
8.60%
Immunovant, Inc. stock logo
IMVT
Immunovant
5.90%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
16.01%
MorphoSys AG stock logo
MOR
MorphoSys
0.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
Immunome, Inc. stock logo
IMNM
Immunome
4087.01 million79.53 millionOptionable
Immunovant, Inc. stock logo
IMVT
Immunovant
120170.92 million160.84 millionOptionable
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
17065.12 million54.69 millionOptionable
MorphoSys AG stock logo
MOR
MorphoSys
730150.62 million150.55 millionNot Optionable

Recent News About These Companies

Novartis to shut MorphSys sites amid pelabresib delay
Novartis sheds MorphoSys staff, sites after pelabresib delay
Novartis shutters MorphoSys sites, lays off staff
Novartis raises mid-term sales guidance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Immunome stock logo

Immunome NASDAQ:IMNM

$8.89 +0.34 (+3.98%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$8.88 -0.02 (-0.17%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Immunovant stock logo

Immunovant NASDAQ:IMVT

$17.29 +0.40 (+2.37%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$17.32 +0.03 (+0.15%)
As of 06:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Kymera Therapeutics stock logo

Kymera Therapeutics NASDAQ:KYMR

$45.18 +1.75 (+4.03%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$44.54 -0.64 (-1.42%)
As of 05:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

MorphoSys stock logo

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)
As of 07/8/2025

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.